Ian D. Davis

Active 1991–2026

135
Papers
22,130
Citations
71
h-index
124
i10-index

Citations

Citations per year for Ian D. Davis1992: 1 citations1993: 5 citations1994: 3 citations1995: 5 citations1996: 4 citations1997: 4 citations1998: 3 citations1999: 4 citations2000: 3 citations2001: 1 citations2002: 6 citations2003: 17 citations2004: 40 citations2005: 52 citations2006: 58 citations2007: 68 citations2008: 73 citations2009: 91 citations2010: 94 citations2011: 124 citations2012: 125 citations2013: 79 citations2014: 113 citations2015: 150 citations2016: 150 citations2017: 150 citations2018: 143 citations2019: 469 citations2020: 652 citations2021: 796 citations2022: 637 citations2023: 623 citations2024: 1,049 citations2025: 456 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,341 citing papers, 22.8% of this breakdownUnited Kingdom: 729 citing papers, 7.1% of this breakdownGermany: 653 citing papers, 6.4% of this breakdownItaly: 610 citing papers, 5.9% of this breakdownChina: 555 citing papers, 5.4% of this breakdownAustralia: 533 citing papers, 5.2% of this breakdownCanada: 504 citing papers, 4.9% of this breakdownFrance: 488 citing papers, 4.8% of this breakdownNetherlands: 365 citing papers, 3.6% of this breakdownSpain: 319 citing papers, 3.1% of this breakdownJapan: 313 citing papers, 3% of this breakdownSwitzerland: 291 citing papers, 2.8% of this breakdown
0%22.8%Other 25%

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology12.5%
  • Immunology and Microbiology9.3%
  • Psychology0.7%
  • Social Sciences0.5%
  • Economics, Econometrics and Finance0.4%
  • Other2.7%

Topics

  • Prostate Cancer Treatment and Research13.3%
  • Prostate Cancer Diagnosis and Treatment7.7%
  • Radiopharmaceutical Chemistry and Applications5.5%
  • Cancer Immunotherapy and Biomarkers4.3%
  • Renal cell carcinoma treatment4.1%
  • Immunotherapy and Immune Responses3.8%
  • Other61.3%

Coauthors

All papers

Open in search
  1. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang - The Lancet 2021 cited by 1,082

  2. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Zielinski, Christopher J. Sweeney - New England Journal of Medicine 2019 cited by 1,593

  3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 3,031

  4. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 cited by 787

  5. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang, Sonia Yip, Alison Y. Zhang - The Lancet Oncology 2022 cited by 266

  6. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip - The Lancet Oncology 2023 cited by 199

  7. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastién J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Dearbhaile O'Donnell, Peter C.C. Fong, Alvin Tan, Simon Chowdhury and 13 more - The Lancet Oncology 2023 cited by 188

  8. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  9. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz and 133 more - The Lancet Oncology 2022 cited by 278

  10. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S. Hofman, Margaret McJannett, Andrew Martin, Martin R. Stockler, Ian D. Davis - The Lancet Oncology 2024 cited by 155

  11. Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial

    Authors: , , , , , - The Lancet Healthy Longevity 2022 cited by 211

  12. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 2,483

  13. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  14. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 363

  15. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 cited by 643

  16. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 55

  17. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter C. Black, Enrique Grande, Sanjeev Mariathasan - Cell Reports Medicine 2024 cited by 54

  18. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , - European Urology 2022 cited by 106

  19. AT RISK

    Authors: , , , - 1994 cited by 602

  20. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip W. Kantoff, Raja B. Khauli, Raya Leibowitz‐Amit, Chris Logothetis, Fernando Cotait Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind M’rabti, Declan G. Murphy, Vedang Murthy, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal D. Shore, Eric J. Small, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge M. van Oort, A. Zapatero, Aurelius Omlin - European Urology 2020 cited by 395

  21. TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

    Authors: , , , , , , , , , , , , , - British Journal of Urology 2019 cited by 162

  22. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 133

  23. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert J. Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz‐Amit, Chris Logothetis, Fernando Cotait Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind M’rabti, Declan G. Murphy, Vedang Murthy, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Rob E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal D. Shore, Iwona Skoneczna, Eric J. Small, Matthew R. Smith, Howard R. Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Mary‐Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge M. van Oort, Kosj Yamoah, Dingwei Ye, A. Zapatero, Aurelius Omlin - European Urology 2022 cited by 128

  24. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather H. Cheng, Kim N., Caroline S. Clarke, Noel W. Clarke, Johann S. de Bono, Maria De Santis, Ignacio Durán, Eleni Efstathiou, Onyeanunam Ngozi Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valérie Fonteyne, Nicola Fossati, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Anthony M. Joshua, R. Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Mika Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Raphaële Renard‐Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward M. Schaeffer, Howard I. Scher and 21 more - European Urology 2024 cited by 115